Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
ADRM1
REST API REST API
Homo sapiens
ADRM1 is differentially expressed in 231 experiments: 97 organism parts: testis, liver, ... (95 more);, 133 disease states: normal, colon carcinoma, ... (131 more);, 52 cell types 318 cell lines 34 compound treatments and 69 other conditions.
Synonyms GP110, Rpn13, ARM1
Orthologs ADRM1_BOVIN (Bos taurus)   Gm9774 (Mus musculus)   ENSCING00000006808 (Ciona intestinalis)   ADRM1 (Gallus gallus)   Adrm1 (Rattus norvegicus)   adrm1b (Danio rerio)   Adrm1 (Mus musculus)   F1M930_RAT (Rattus norvegicus)   CG6789 (Drosophila melanogaster)   CG13349 (Drosophila melanogaster)   adrm1 (Xenopus laevis)   ADRM1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term proteasome complex, protein binding, cytoplasm, proteasome assembly, membrane fraction, integral to plasma membrane, nucleus, protease binding, proteasome binding, endopeptidase activator activity, transcription elongation from RNA polymerase II promoter, positive regulation of endopeptidase activity
InterPro Term 26S_Psome_Ubiquitin-recp_Rpn13
UniProt Accession Q16186, E9PEC0
Search EB-eye ENSG00000130706
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-AFMX-5, E-GEOD-803, E-MEXP-1251, E-GEOD-7224, ... (20 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, E-GEOD-18005, ... (31 experiments)

Factor Value U/D Experiments
SW480
4
E-MEXP-1014, E-GEOD-18005, E-GEOD-2509, E-MTAB-37
CCRFCEM
2
E-MTAB-37, E-GEOD-24147
MCF7
2
E-GEOD-5258, E-MTAB-37
MDA-MB-231
2
E-TABM-420, E-MTAB-62
MOLT4
2
E-MTAB-62, E-MTAB-37
HL-60
1
2
E-GEOD-5258, E-GEOD-24147, E-MTAB-37
312 more value(s).


Cell type

studied in E-GEOD-22373, E-GEOD-21668, E-GEOD-20677, E-GEOD-13987, E-TABM-34, ... (28 experiments)

Factor Value U/D Experiments
mononuclear
1
E-GEOD-13987
cancer cell culture
1
E-GEOD-14990
plasmacytoid dendritic cell
1
E-TABM-34
iPS cells from episomal vectors (Defined Factor sub-clone)
1
E-GEOD-20033
centrocyte
1
E-TABM-702
CD4+ T cell
7
1
E-GEOD-6740
46 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-6872, E-GEOD-15960, E-MEXP-1121, E-GEOD-20602, ... (46 experiments)

Factor Value U/D Experiments
colon carcinoma
1
3
E-MTAB-62, E-MTAB-37, E-GEOD-3726, E-MTAB-57
control
2
E-GEOD-20602, E-GEOD-16363
lung adenocarcinoma
2
E-GEOD-2514, E-MTAB-62
acute promyelocytic leukemia
2
E-MTAB-62, E-GEOD-995
gastric carcinoma
2
E-MTAB-37, E-GEOD-2685
malignant melanoma
2
E-GEOD-3189, E-MTAB-62
127 more value(s).


Compound treatment

studied in E-GEOD-571, E-GEOD-6907, E-GEOD-5741, E-GEOD-15205, E-GEOD-5824, ... (20 experiments)

Factor Value U/D Experiments
5-fluorouridine
1
E-GEOD-995
Cxcl12
1
E-GEOD-7307
5-aza-2'-deoxycytidine + trichostatin A
1
1
E-MEXP-1269
placebo
1
E-MEXP-1327
bis [(+)-tartrato] diantimonate (III) dipotassium trihydrate
1
E-GEOD-6907
LDL
1
E-GEOD-5741
28 more value(s).


Age at diagnosis

studied in E-GEOD-3494, E-GEOD-4922

Factor Value U/D Experiments
86 years
1
E-GEOD-4922
86
1
E-GEOD-3494


Agent
studied in E-GEOD-19519

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-TABM-234, E-GEOD-7967, E-GEOD-21589, ... (6 experiments)

Clinical info
studied in E-MTAB-37, E-GEOD-17189, E-GEOD-6710, E-GEOD-19348, E-MEXP-1251, ... (8 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-1614, E-GEOD-20033, E-GEOD-3140, E-MTAB-62

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-89, E-GEOD-2509, E-TABM-147, E-GEOD-21138, E-GEOD-1751, ... (6 experiments)

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-MEXP-1482, E-GEOD-17385, E-GEOD-20847, E-MEXP-563

Genotype
studied in E-GEOD-3494, E-GEOD-2466, E-GEOD-17476, E-TABM-601, E-GEOD-17347 ... (5 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-7011, E-MEXP-2657, E-TABM-127, E-MEXP-1446 ... (5 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Her2 status
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276, E-GEOD-20194, E-GEOD-16716

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-1926, E-GEOD-16363, E-GEOD-430, ... (25 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-GEOD-17400

Karyotype
studied in E-GEOD-7214, E-GEOD-22056

Ki67 ihc
studied in E-GEOD-21653

Light
studied in E-GEOD-1725

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-LGCL-5

Phenotype
studied in E-GEOD-19703, E-GEOD-22152, E-GEOD-21750, E-GEOD-2487, E-GEOD-4600 ... (5 experiments)

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

RNAi
studied in E-GEOD-12438, E-MEXP-1509, E-GEOD-1676, E-MEXP-101, E-GEOD-3697, ... (6 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-MEXP-70

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-1643, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276, E-GEOD-2748

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-16837, E-GEOD-21909, E-GEOD-19246, E-GEOD-19815, E-GEOD-12198 ... (5 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-3494, E-TABM-43, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.448 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM